3/25
12:33 pm
incy
Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.
Low
Report
Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.
3/25
09:00 am
incy
Incyte Announces Executive Leadership Appointments
Low
Report
Incyte Announces Executive Leadership Appointments
3/25
08:03 am
incy
Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
Low
Report
Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
3/24
09:02 pm
incy
Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.
Low
Report
Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.
3/22
11:12 pm
incy
Incyte: An Undervalued Healthcare Gem [Seeking Alpha]
Low
Report
Incyte: An Undervalued Healthcare Gem [Seeking Alpha]
3/20
10:00 am
incy
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Low
Report
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
3/18
06:39 pm
incy
Incyte (INCY) was downgraded by
Weiss Ratings from "buy (b-)" to "hold (c+)".
Low
Report
Incyte (INCY) was downgraded by
Weiss Ratings from "buy (b-)" to "hold (c+)".
3/18
11:27 am
incy
Incyte at Barclays: Maps Post-Jakafi Growth With New Launches and Phase III Pipeline Push [Yahoo! Finance]
Low
Report
Incyte at Barclays: Maps Post-Jakafi Growth With New Launches and Phase III Pipeline Push [Yahoo! Finance]
3/17
08:57 pm
incy
Tracking Baker Brothers Portfolio - Q4 2025 Update [Seeking Alpha]
Low
Report
Tracking Baker Brothers Portfolio - Q4 2025 Update [Seeking Alpha]
3/17
10:26 am
incy
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue [Seeking Alpha]
Low
Report
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue [Seeking Alpha]
3/17
08:13 am
incy
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico [Yahoo! Finance]
Low
Report
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico [Yahoo! Finance]
3/17
07:42 am
incy
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
3/17
07:30 am
incy
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
Low
Report
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
3/16
03:56 pm
incy
Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond [Seeking Alpha]
Low
Report
Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond [Seeking Alpha]
3/16
08:43 am
incy
Incyte (INCY) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $94.00 price target on the stock.
Neutral
Report
Incyte (INCY) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $94.00 price target on the stock.
3/14
10:23 pm
incy
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer [Yahoo! Finance]
Low
Report
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer [Yahoo! Finance]
3/13
10:14 am
incy
2 Value Stocks to Consider Right Now and 1 We Ignore [Yahoo! Finance]
Low
Report
2 Value Stocks to Consider Right Now and 1 We Ignore [Yahoo! Finance]
3/11
11:06 am
incy
Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
12:18 pm
incy
Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/10
10:21 am
incy
1 Under-the-Radar Biotech to Buy for Potential 10X Growth in the Next Decade [Yahoo! Finance]
Low
Report
1 Under-the-Radar Biotech to Buy for Potential 10X Growth in the Next Decade [Yahoo! Finance]
3/10
07:32 am
incy
Prelude Therapeutics GAAP EPS of -$1.29 misses by $0.04, revenue of $12.14M [Seeking Alpha]
Low
Report
Prelude Therapeutics GAAP EPS of -$1.29 misses by $0.04, revenue of $12.14M [Seeking Alpha]
3/10
06:43 am
incy
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz [Yahoo! Finance]
Low
Report
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz [Yahoo! Finance]
3/9
08:03 am
incy
Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
Low
Report
Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
3/7
09:23 am
incy
Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant [Seeking Alpha]
Low
Report
Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant [Seeking Alpha]
3/6
04:42 pm
incy
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Low
Report
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)